ADARx Pharmaceuticals, a Phase 3 biotech developing siRNA therapies for various diseases, raised $446 million by offering 26.3 million shares at $17, the high end of the $15 to $17 range. It had originally planned to offer 21.9 million shares. AbbVie agreed to...read more
ADARx Pharmaceuticals, a phase 3 biotech developing siRNA therapies for various diseases, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $350 million by offering 21.9 million shares at a price range of $15 to $17. AbbVie...read more
Updated Monday, 9/21. Three IPOs are scheduled for the week ahead, though smaller deals may join the calendar late. Homeowners insurance MGU Bamboo Insurance Services (BMB) plans to raise $665 million at a $3.3 billion market cap. Bamboo manages functions...read more
ADARx Pharmaceuticals, a Phase 3 biotech developing siRNA therapies for various diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. ADARx Pharmaceuticals is focused on developing next-generation small interfering...read more
siRNA biotech ADARx Pharmaceuticals prices upsized IPO at $17, the high end of the range
ADARx Pharmaceuticals, a Phase 3 biotech developing siRNA therapies for various diseases, raised $446 million by offering 26.3 million shares at $17, the high end of the $15 to $17 range. It had originally planned to offer 21.9 million shares. AbbVie agreed to...read more
siRNA biotech ADARx Pharmaceuticals sets terms for $350 million IPO
ADARx Pharmaceuticals, a phase 3 biotech developing siRNA therapies for various diseases, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $350 million by offering 21.9 million shares at a price range of $15 to $17. AbbVie...read more
US IPO Week Ahead: Insurance, biotech, and defense materials set to test the IPO market
Updated Monday, 9/21. Three IPOs are scheduled for the week ahead, though smaller deals may join the calendar late. Homeowners insurance MGU Bamboo Insurance Services (BMB) plans to raise $665 million at a $3.3 billion market cap. Bamboo manages functions...read more
siRNA biotech ADARx Pharmaceuticals files for a $100 million IPO
ADARx Pharmaceuticals, a Phase 3 biotech developing siRNA therapies for various diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. ADARx Pharmaceuticals is focused on developing next-generation small interfering...read more